SCHEMBL24265694

SCHEMBL24265694

c1ccc(Cn2ncc3ccc(N4CCNCC4)nc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR3A P46098 4/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ HTR3E A5X5Y0 3/20 0.49
▸ HTR3B O95264 3/20 0.49
▸ HTR3D Q70Z44 3/20 0.49
▸ HTR3C Q8WXA8 3/20 0.49
▸ HTR6 P50406 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ CYP3A4 P08684 2/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ USP2 O75604 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ ADRB1 P08588 1/20 0.49
▸ HTR1A P08908 1/20 0.49
▸ HTR2C P28335 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ SLC6A4 P31645 1/20 0.49
▸ HTR7 P34969 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ PMP22 Q01453 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24265687 0.75 CKS1B (0.53) MAPT
SCHEMBL30548155 0.75 CKS1B (0.53) MAPT
SCHEMBL24265729 0.73 HTR6 (0.57) HTR3AALDH1A1HTR3EHTR3BHTR3D
SCHEMBL24265819 0.73 HRH3 (0.38) HTR3AALDH1A1HTR3EHTR3BHTR3D
SCHEMBL24265692 0.73 RECQL (0.56) ALDH1A1KDM4EHSD17B10MAPK1HTT
SCHEMBL5864286 0.72 HTR2C (0.51) HTR3AALDH1A1HTR3EHTR3BHTR3D
SCHEMBL14919677 0.72 RECQL (0.54) ALDH1A1KDM4EHSD17B10MAPK1HTT
SCHEMBL24265510 0.72 HTR3A (0.49) HTR3AALDH1A1HTR3EHTR3BHTR3D
SCHEMBL24851850 0.69 CDK4 (0.41) HTR3AALDH1A1CYP1A2HTTPKM
SCHEMBL8352589 0.68 HTR3A (0.61) HTR3APIM1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 — — US disclosed
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 — — US disclosed
CN-116507326-A Compounds as GLP-1R agonists 拓臻制药公司 2023-07-28 — — CN disclosed
EP-4199919-A1 COMPOUNDS AS GLP-1R AGONISTS Terns Pharmaceuticals, Inc. (US) 2023-06-28 — — EP disclosed
WO-2022040600-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. (US) 2022-02-24 — — WO disclosed
WO-2022040600-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. (US) 2022-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR HTR3A 197/4885ALDH1A1 3522/4885HTR3E 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback